Opendata, web and dolomites

DUBs26S SIGNED

Role of a novel proteasome-associated DUB – A boon for therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DUBs26S project word cloud

Explore the words cloud of the DUBs26S project. It provides you a very rough idea of what is the project "DUBs26S" about.

tools    networking    fact    multisubunit    site    proposes    human    active    relevance    job    processivity    clinical    training    committed    drug    cells    extraordinarily    proteins    subunit    incorporation    dubs    unravel    instigate    dub    static    enzymatic    interaction    fixed    embellished    goals    applicative    conserved    eukaryotic    opens    alter    search    ensures    neurodegeneration    specificity    reciprocal    tissue    redundant    efforts    shatters    enzymes    proteasome    deubiquitinating    tweaks    notion    career    drugable    clinically    clearing    live    action    experimental    association    healthy    myriad    fruition    msc    embark    enzyme    subset    usp9x    preparation    composition    investigation    msca    26s    usp14    disposal    life    respective    host    replacing    l5    purified    competencies    found    crux    ubiquitin    strategies    labs    fits    independent    researcher    realign    relationship    structure    spheres    basic    largely    complexes    proposing    phyla    uch    span    cancers    expanded    substrate    reported   

Project "DUBs26S" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 182˙509 €
 EC max contribution 182˙509 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 182˙509.00

Map

 Project objective

Clearing-up old or redundant proteins is essential for cells to live; this job is largely done by 26S Proteasome. The multisubunit complex – 26S Proteasome – is extraordinarily conserved throughout all eukaryotic phyla, in terms of subunit composition and overall structure. However, in preparation of this research proposal, the Researcher found a novel association of 26S proteasome with a clinically important deubiquitinating enzyme (DUB), USP9X. In a subset of proteasome purified from human tissue by the Researcher, USP9X was in fact the major DUB replacing commonly reported enzymes (USP14, UCH-L5). This finding shatters the notion of proteasome as a static, fixed, complex, and opens up the search for expanded spheres of interaction. The crux of this MSC-IF action is the reciprocal relationship between 26S proteasome and USP9X. Using myriad experimental tools at his disposal, the Researcher proposes to unravel how this novel association tweaks each of their respective enzymatic properties. Incorporation of USP9X may alter substrate specificity and processivity of proteasome, as well as its own enzymatic properties. Even in the immediate term, this proposal will realign research efforts – both basic and applicative – towards USP9X as the new drugable target in the ubiquitin-proteasome system. This new enzymatic active site on proteasome complexes will instigate investigation into the cause of USP9X in neurodegeneration and various cancers. This MSCA-IF fits current European challenges to increase healthy life span by proposing strategies for drug design against DUBs of clinical relevance. Two host labs are committed to provide the Researcher with the best training and support to bring his research to fruition and embark his independent career. Novel experimental findings embellished with new technical competencies and networking experience ensures the Researcher’s future career goals.

 Publications

year authors and title journal last update
List of publications.
2019 Indrajit Sahu, Sachitanand M Mali, Prasad Sulkshane, Andrey Rozenberg, Cong Xu, Roni Morag, Manisha Priyadarsini Sahoo, Sumeet K Singh, Zhanyu Ding, Yifan Wang, Sharleen Day, Yao Cong, Oded Kleifeld, Ashraf Brik, Michael H Glickman
Signature activities of 20S proteasome include degradation of the ubiquitin-tag with the protein under hypoxia
published pages: , ISSN: , DOI: 10.1101/2019.12.20.883942
BioRxIV 2020-01-29
2019 Zhanyu Ding, Cong Xu, Indrajit Sahu, Yifan Wang, Zhenglin Fu, Min Huang, Catherine C.L. Wong, Michael H. Glickman, Yao Cong
Structural Snapshots of 26S Proteasome Reveal Tetraubiquitin-Induced Conformations
published pages: , ISSN: 1097-2765, DOI: 10.1016/j.molcel.2019.01.018
Molecular Cell 2019-05-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DUBS26S" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DUBS26S" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  

GenEl (2020)

General readout electronics for cross-sectoral application in European research infrastructure

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More